Model-Informed Abatacept Dose Recommendation in Pediatric Patients With Acute Graft Versus Host Disease.

ABSTRACT: This study uses a population pharmacokinetic (PPK) approach to provide abatacept dosing recommendations in pediatric patients 2 to < 6 years of age receiving unrelated donor hematopoietic stem cell transplantation (HSCT) due to hematologic malignancies (HMs), for the prophylaxis of acute graft-versus-host disease (aGVHD). An intermediate PPK model was developed and refined to include data from 904 patients aged 2-17 years with juvenile idiopathic arthritis administered with subcutaneous abatacept. Then, PK simulations were performed using the final PPK model for virtual pediatric patients aged 2 to < 6 years administered with either intravenous abatacept, fixed abatacept doses, or loading doses followed by maintenance dosing. The final model characterized abatacept exposure well using a li

SUBMITTER: Zhong R 

PROVIDER: S-EPMC12902727 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature